Pharmacology of Aflibercept (Eylea, Zaltrap) ; Pharmacokinetics, Mechanism of Action, Uses, Effects скачать в хорошем качестве

Pharmacology of Aflibercept (Eylea, Zaltrap) ; Pharmacokinetics, Mechanism of Action, Uses, Effects

Aflibercept (marketed as Eylea and Zaltrap) is a recombinant fusion protein used to treat various conditions, including eye diseases and cancer. Here's an overview of its pharmacology: Mechanism of Action Aflibercept acts as a VEGF (vascular endothelial growth factor) inhibitor. It binds to VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing them from interacting with their receptors on endothelial cells. This inhibition reduces angiogenesis (formation of new blood vessels) and vascular permeability, which are key factors in diseases like wet age-related macular degeneration (AMD) and metastatic colorectal cancer. Pharmacokinetics Administration: Eylea: Intravitreal injection for ocular conditions. Zaltrap: Intravenous infusion for cancer treatment. Absorption: Localized action in the eye for Eylea; systemic distribution for Zaltrap. Metabolism: Metabolized into smaller peptides and amino acids. Excretion: Primarily through the kidneys. Clinical Uses Eylea: Neovascular (wet) AMD. Diabetic macular edema (DME). Macular edema following retinal vein occlusion (RVO). Diabetic retinopathy. Zaltrap: Used in combination with chemotherapy (FOLFIRI regimen) for metastatic colorectal cancer resistant to oxaliplatin-based therapy. Adverse Effects Eylea: Common: Eye pain, conjunctival hemorrhage, and increased intraocular pressure. Serious: Endophthalmitis and retinal detachment. Zaltrap: Common: Fatigue, diarrhea, and hypertension. Serious: Hemorrhage, gastrointestinal perforation, and thromboembolic events. Precautions Contraindicated in patients with active infections or inflammation near the injection site (Eylea). #Aflibercept